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Received May 26, 2017; accepted July 24, 2017AbstractBackground: Herpes simplex virus type 2 (HSV-2) infectious disease is one of the most common viral sexually transmitted diseases. As regards,
vaginal lactobacilli play an important role in protecting host against the urogenital pathogens; here we assessed the potential antiviral activity of
Lactobacillus crispatus against HSV-2 infection in vitro.
Methods: Both Vero and HeLa cell lines were treated by L. crispatus before, during and after HSV-2 infection. The pre-incubation assay was also
performed for the evaluating of virus adsorption by L. crispatus. Virus titer reduction in each stage was determined by a plaque reduction assay.
Results: L. crispatus significantly decreased the infectivity of the HSV-2 in initial steps on both cell lines; however, no significant inhibition was
ascertained during adsorption and multiplication process. The lactobacilli adhere on Vero cells two-fold stronger than HeLa and subsequently
protect the Vero cells nearly 2.5 fold higher than HeLa cell against the virion. Co-incubation of HSV-2 with bacterial cells prior to virus
inoculation significantly decreased the virus titer.
Conclusion: L. crispatus appears to inhibit the entry of the virus into cells by trapping HSV-2 particles. In addition, formation of L. crispatus
microcolonies in the cell surface could block HSV-2 receptors and prevent viral entry to cells in initial infection steps.
Copyright © 2017, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Herpes simplex virus (HSV-2) is a member of the herpes-
viridiae family and the principal species responsible for gen-
ital herpes.1 HSV-2 produces localized lesions on skin and
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drugs, such as acyclovir, valacyclovir, and famciclovir are
used to treat HSV-2. Resistance to the many of these drugs,
especially acyclovir, has been increasingly reported.3 There-
fore, new strategies for prophylactic and treatment of HSV-2
infection are necessary.
It has been reported that any disturbance in the population
of normal microbiota of the vagina gives rise to a risk of
urogenital tract infections, such as bacterial vaginosis, candi-
diasis, and viral sexually transmitted diseases.4,5 Clinical
studies have demonstrated that an abnormal vaginal flora is a
risk factor for harboring HSV-2 and human papillomavirus
(HPV) viruses.6,7 Lactobacilli are part of the vaginal micro-
biota of healthy females,8 and several studies have investigatedsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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HSV, but the mechanism of action of lactobacilli in combating
HSV infection remains unclear.9e12 Numerous mechanisms
have been proposed for the protection of the epithelial layer of
the vagina against invasion pathogens. These include secreted
bacterial metabolites (lactic acid, hydrogen peroxide, and
bacteriocin), stimulation of innate immunity, and competition
for epithelial cell receptors.13,14 One of the most important
characteristics of lactobacilli is their ability to colonize
epithelial and mucosal cells, thereby preventing invasion by
pathogens of these cells.15,16 Lactobacilli might inhibit viral
multiplication via competition for attachment to cell receptors
or via induction of epithelial cells to produce antimicrobial
substances.17 Normal vaginal microbiota has been composed
with more than 20 species of lactobacilli that their charac-
teristics and proportions vary in different ethnic groups.18 As
regards, Lactobacillus crispatus is one of the dominant species
colonized in the healthy female vagina; it would be interesting
to verify inhibitory effect of this strain against HSV-2.19
The Vero cell line, derived from African green monkey
kidney cells, is competent for the replication of many human
viruses, including HSV-2.20 In the present study, to understand
the probable interference of lactobacilli with the viral infec-
tion in the human cells, HeLa cells, derived from human tis-
sues was used, as well as Vero cells, to examine the potential
role of L. crispatus in combatting HSV-2 infection.
2. Methods2.1. Virus, cell lines and bacteriaHSV-2 strain was purchased from Tarbiat Modares Uni-
versity, Tehran, Iran. The virus was propagated in Vero and
HeLa cell lines (provided from Razi institute, Iran). A titer of
107 PFU/ml of the virus was determined by a plaque assay, and
viral particles with a multiplicity of infection (MOI) of 0.01
were used in all the experiments. Both Vero and HeLa cells
were maintained in Dulbecco's Modified Eagles Medium
(DMEM, Gibco-Germany), supplemented with 10% fetal
bovine serum (Gibco-Germany) and 1% penicillin/strepto-
mycin (Gibco-Germany) and incubated at 37 C with 5% CO2.
Our previously reported isolate, L. crispatus KP090111, from
the vagina of a healthy Iranian female was used as a probiotic
candidate in this study.21 The isolated bacterium was main-
tained in de Man Rogosa-Sharp (MRS, Merck-Germany) broth
containing 20% glycerol at 70 C. Viable microorganisms
were counted by plating serial 10-fold dilutions of the bacte-
rial suspension on MRS agar after incubation for 48 h. Based
on colony-forming units, the number of viable bacteria in 1 ml
of the suspension after 24 h was determined as 108 CFU/ml.
Using spectrophotometry, the optical density at this concen-
tration was equal to 2.2.2. Determination of the cytotoxicity of L. crispatusTo evaluate the possible cytotoxicity of the lactobacilli in
the cell lines, a serial dilution of bacteria was prepared, andeach dilution was added to a cell monolayer of both Vero and
HeLa cells cultured on 96-well plates. The survival ability of
the cells was determined by methylthiazolyl-diphenyl-
tetrazolium bromide (MTT) assay. Briefly, bacterial cells
from an overnight suspension culture of L. crispatus were
collected and washed with Phosphate-buffered saline (PBS).
The pellet was resuspended in DMEM without antibiotics at
different concentrations (104, 105, 106, 107, and 108 CFU/ml).
Then, 100 ml of each bacterial dilution was added to each well
and the microplate was incubated at 37 C with 5% CO2 for
24 h. Cells were then washed with PBS three times, and 180 ml
of fresh DMEM and 20 ml of MTT (5 mg/ml) were added to
each well and the plate was incubated at 37 C for 4 h. Finally,
after addition of DMSO, an ELISA reader (Tekan-Germany)
read the optical density (OD) at 570 nm. The percentage of
cell viability was calculated according to the Kassaa et al.12
Cells with DMEM were used as a negative control.2.3. Adhesion of L. crispatus to Vero and HeLa cellsThe ability of bacterium to attach to the target cells was
determined as previously described.21 Briefly, overnight culture
of L. crispatus was collected, washed with PBS, and resus-
pended in DMEM to a final concentration of 108 CFU/ml. Then
a bacterial suspension with CFU/cell ratio of 100 was added to
the monolayer of target cells in 24 well-plates. After 4 h in-
cubation at 37 C, the cell monolayer was washed with PBS
three times to remove free bacteria from the well. The cells
were detached from the well by trypsin 0.05% and resuspended
in DMEM. The total number of viable bacteria adhered to the
cells was determined by the colony counting method.2.4. Antiviral activity of the bacterial supernatantOvernight culture of L. crispatus was washed in PBS and
5  106 CFU resuspended in DMEM. The suspension was
maintained at 37 C for 24e48 h. The bacterial suspension
was then centrifuged for 10 min at 10,000 g at 4 C, the su-
pernatant was collected, and the pH was neutralized with
NaOH 1M in a sterile condition.2.5. In vitro interference experimentsFor interference studies, infection of the Vero and HeLa
cells (concentration of 105 cells/well) with HSV-2 was per-
formed at a MOI of 0.01. The suspension of L. crispatus was
applied to the cell culture, at a concentration of 107 CFU/ml
(100 CFU/cell), in three different stage of the HSV-2 life cycle
that let us to know at which step during viral cycle, the
addition of the lactobacillus is most effective. In the first series
of the experiment, named pre-treatment, the cells were treated
first with a suspension of L. crispatus for 1.5 h, and then
supplemented with HSV-2 for 1 h. In second series of the
experiments, named competition, the cells were concurrently
exposed to the bacterium and HSV-2 for 1 h; they were also
first exposed to the virus for 1 h and then to the bacteria
without washing in the third series of experiments so called
Fig. 1. Effect of L. crispatus on the viability of the cell line. Cell viability was
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mental setup for studying the interference was depicted in
Supplementary Fig. 1. After 24 h incubation of the cells at
37 C, the supernatant of each well was collected and titered
for infectivity of HSV-2 on Vero and HeLa cells by plaque
reduction assay.
In another experiment, named pre-incubation (See S
Fig. 1), direct interaction between bacteria and the virus par-
ticles in a cell free system was evaluated. Briefly, a microtube
containing the lactobacilli and viral particles was incubated
for 2 h at room temperature. The microtube was then centri-
fuged for 10 min at 4000 g and the supernatant was subjected
to the aforementioned plaque assay analysis. All experiments
were performed in triplicate for a minimum of six wells.tested by an MTT assay after 24 h. The concentration of bacteria with the least
cytotoxic effect was 107 CFU/ml.
2.6. Plaque reduction assayThe titer of the virus was determined by plaque assay.
Nearly, 4  105 cells/well were seeded in six well plates and
incubated for 24e48 h to reach at least 98% of confluence.
The collected supernatants were serially diluted and 500 ml of
each dilution were added to each well. The plate was incu-
bated at 37 C for 1 h to allow attachment of the virus to the
cells. The supernatant was then removed from each well, and
3 ml of 1.5% DMEM/agar was added to each well. The plates
were incubated for 48e72 h until the formation of plaques.
Neutral red at a concentration of 0.01 was added to each well
and incubated for 24 h. The plaques were then counted. A
reduction in the number of plaques in each experiment was
determined by comparison with a positive control (a suspen-
sion of the viruses with MOI of 0.01).2.7. Statistical analysisFig. 2. The ability of L. crispatus to adhere to Vero and HeLa cells. Data was
shown as % adhesion. The efficiency of adhesion on cell lines was 12.33% and
5.8% respectively.All calculations were performed with IBM SPSS software,
version 22. ANOVA, followed by a Least Significant Differ-
ence (LSD) test that performed to compare the reduction in the
viral titer in each of the experiments. The P value of <0.05
was considered statistically significant. All the data are given
as the mean ± SD.
3. Results3.1. Evaluation of the L. crispatus effect on the cell
viability and its capability to attachment to the cellsBased on the cytotoxicity assay of L. crispatus on Vero and
HeLa cells, the cell viability was dramatically decreased when
the concentration of lactobacilli raised from 107 CFU/ml to
108 CFU/ml (Fig. 1). Thereby, an optimum concentration of
107 CFU/ml was applied in all the interference experiments.
The bacterial adhesion was measured after 2 h co-
incubation of the bacteria and both Vero and HeLa cells. As
shown in Fig. 2 the results were expressed as a percentage of
the initial bacterial count.22 The percentage of adhering bac-
teria to Vero and HeLa cells was 12% (SD ¼ 2.5) and 5.8%
(SD ¼ 1.2) respectively.3.2. Evaluation of virus titer reduction in the cells
treated with L. crispatusAs delineated in Fig. 3, amongst the three interference
experiments, a significant antiviral activity of the L. crispatus
was shown in the pre-treatment step on both Hela and Vero
cells. But, the titer of HSV-2 was more decreased in the Vero
than HeLa cell line. However, in the both cell lines, neither in
competition stage, when virus and bacteria simultaneously
were presented on cells, nor in post-infection, which bacteria
were added after adsorption of the virus into the cells, there
was no significant reduction in the HSV-2 titer.3.3. Virus adsorption by the bacteria in pre-incubation
assayThe analysis of HSV-2 adsorption by L. crispatus showed
that the virus titer of the supernatant was dramatically
decreased after 2 h incubation of the bacteria and the viruses in
a cell free condition (Fig. 3).
Fig. 3. Inhibition of HSV-2 multiplication by L. crispatus. The reduction of the virus titer was measured by a plaque assay. The results were mean ± standard
deviations from three independent experiments.
265E. Mousavi et al. / Journal of the Chinese Medical Association 81 (2018) 262e2673.4. Antiviral activity of the bacterial supernatantNo significant changes in the virus infectivity were
observed after 2 h co-incubation of the bacterial supernatant
and the HSV-2 at room temperature on both Vero and HeLa
cell lines (Fig. 4).
4. Discussion
HSV-2 is one of the most prevalent etiologies of sexually
transmitted diseases, a risk factor for acquiring HIV.23 Clinical
and animal studies have demonstrated that lactobacilli play an
important role in the prevention of viral infections.24 Vaginal
microbiota inhibits the viral infection by several postulated
mechanisms such as production of active metabolites,Fig. 4. Reduction of viral titer in bacterial supernatant. The results werformation physical barrier against pathogen adhesion on
epithelial cells,24 physical interaction to the virus envelope12,25
and stimulation of the immune system.26 In this study, we
assessed the potential anti-HSV activity of L. crispatus, which
is one of the most dominant lactobacillus species isolated from
healthy women vagina.21,27
It has been shown that pre-treatment of Lactobacillus
gasseri strain on Vero cells dramatically inhibited the infec-
tivity of HSV 1 & 2.11,12 Consistently, on HeLa and Vero cell
lines, L. crispatus significantly decreased the infectivity of the
virion in initial steps by 26e49%, respectively (Fig. 3).
However, presence of the metabolically active bacterial cells
during or after infection process have the same results as
control (Fig. 3). As previously reported co-incubation of the
bacteria and HSV-2 at the CFU/PFU ratio of 1e100,000 one mean ± standard deviations from three independent experiments.
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Similarly, our results showed that virus particles adsorbed
more effectively than bacteria on cell membrane but antiviral
activity increased when the PFU/CFU ratio reduced from 10 to
1 (data not shown). Also after entry of the virus particles to the
cells no further inhibition was induced by the lactobacilli on
intracellular virus replication process (Fig. 3). Overall, these
results suggested that physical interaction or active metabo-
lites of the lactobacilli inhibit/block the adsorption of HSV-2
to the cell membrane.10,24,28 Some studies have shown that
the excretion of metabolites, such as lactic acid, bacteriocin
and H2O2, by lactobacilli was contributed in the inactivation
of HSV particles before infection.10,11 So, we examined the
antiviral activity of the L. crispatus secreted metabolites as
described by previous studies.10,12 No significant antiviral
activity was found in the supernatant when the bacteria were
grown in DMEM media (Fig. 4). On the contrary, co-incu-
bation of HSV-2 with bacterial cells prior to virus inoculation
significantly decreased the virus titer by up to 60% (Fig. 3). In
this concept, Lai et al. demonstrated that vaginal lactobacilli
attachment to the surface of HIV prevented the diffusion stage
of this virus.29 Ivec et al. reported that lactobacilli were able to
block virus entry into cells by trapping the VSV particles.25
Kassa et al. also obtained similar results for the inactivation
of HSV-2 particles with attachment of L. gasseri to viral en-
velope.12 These findings are in line with the possibility of virus
inactivation with physical interaction between lactobacilli and
viral envelope.30
Besides, as shown in Fig. 3 the inhibitory effect of the L.
crispatus on the Vero cells was approximately 2.5 fold higher
than HeLa in initial infection steps. This may be described by
nearly two-fold stronger adherence of L. crispatus to Vero cell
line (Fig. 2). The first step of virus entry to a host cell is virus
attachment to the cell receptors, and therefore inhibition of
this attachment could be prevent disease process.33 Lactoba-
cilli may block virus entry to the host cell by masking specific
or non-specific receptors.15,28 Therefore, the second possibility
of virus inactivation by L. crispatus is thought to be exerted
through a physical barrier that formed by the bacterial cells on
cell membrane.28,30 The capability of lactobacilli to attach to
the cells depends on various factors like the cell wall com-
ponents of bacteria, cell receptors and soluble proteins
secreted by the host cells.31 Moreover, previous studies indi-
cated that L. crispatus strains encode adhesion components
named, S-layer proteins that play important role on adherence
of bacteria on Hela cells.32 However, more studies should be
conducted on normal vaginal cell lines to elucidate the adhe-
sion ability of lactobacilli on epithelial cells and protection
against viral infections.
In conclusion, two mechanisms may be involved in the
antiviral effect of lactobacilli towards HSV-2 (1.) formation of
L. crispatus microcolonies in the cell surface could block
HSV-2 receptors and prevent viral entry to cells in initial
infection steps and (2.) entrapment of viral particles by direct
interaction of L. crispatus with HSV-2 envelope.
Since the present results indicate a physical contact be-
tween bacterial cells and viral envelope could inhibit HSV-2infection, it would be interesting to examine the potential
prophylactic properties of L. crispatus cell wall components
against HSV-2 infection in vitro and in vivo.
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